Literature DB >> 13304798

Psychosis and enhanced anxiety produced by reserpine and chlorpromazine.

G J SARWER-FONER, W OGLE.   

Abstract

Entities:  

Keywords:  ANXIETY/etiology and pathogenesis; CHLORPROMAZINE/injurious effects; PSYCHOSES, TOXIC/etiology and pathogenesis; RAUWOLFIA ALKALOIDS/injurious effects

Mesh：

Substances：

Year:  1956        PMID： 13304798      PMCID： PMC1823156     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Clinical uses of rauwolfia. I. In arterial hypertension.

Authors:  J GENEST; L ADAMKIEWICZ; R ROBILLARD; G TREMBLAY
Journal:  Can Med Assoc J       Date:  1955-04-01       Impact factor: 8.262

2.  Oral preparations of Reuwolfia serpentina in treatment of essential hypertension.

Authors:  S LOCKET
Journal:  Br Med J       Date:  1955-04-02

3.  Hypertension treated with Rauwolfia serpentina (whole root) and with reserpine; controlled study disclosing occasional severe depression.

Authors:  R W ACHOR; N O HANSON; R W GIFFORD
Journal:  J Am Med Assoc       Date:  1955-10-29

4.  Psychosis apparently produced by reserpine.

Authors:  H A SCHROEDER; H M PERRY
Journal:  J Am Med Assoc       Date:  1955-10-29

5.  Depression and anxiety occurring during Rauwolfia therapy.

Authors:  J C MULLER; W W PRYOR; J E GIBBONS; E S ORGAIN
Journal:  J Am Med Assoc       Date:  1955-10-29

6.  Psychodynamic aspects of reserpine: its uses and effects in open psychiatric settings.

Authors:  G J SARWER-FONER; W OGLE
Journal:  Can Psychiatr Assoc J       Date:  1956-01

7.  Mental depression in hypertensive patients treated for long periods with large doses of reserpine.

Authors:  E D FREIS
Journal:  N Engl J Med       Date:  1954-12-16       Impact factor: 91.245

8.  The use of reserpine in an open psychiatric setting.

Authors:  G J SARWER-FONER; W OGLE
Journal:  Can Med Assoc J       Date:  1955-08-01       Impact factor: 8.262
  8 in total
  6 in total

1.  On the psychology of the shaking palsy.

Authors:  W R FLYNN
Journal:  Psychiatr Q       Date:  1962-04

2.  Paradoxical reactions to benzodiazepines.

Authors:  R C Hall; S Zisook
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

3.  Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.

Authors:  Evan Kyzar; Adam Michael Stewart; Samuel Landsman; Christopher Collins; Michael Gebhardt; Kyle Robinson; Allan V Kalueff
Journal:  Brain Res       Date:  2013-07-01       Impact factor: 3.252

Review 4.  Witches, potions, and metabolites: an overview from a medicinal perspective.

Authors:  Luana Canzian Llanes; Nathalia Biazotto Sa; Arthur Ribeiro Cenci; Kerolain Faoro Teixeira; Igor Vinícius de França; Lidiane Meier; Aldo Sena de Oliveira
Journal:  RSC Med Chem       Date:  2022-03-30

5.  Clinical investigation of trifluoperazine (stelazine) in open psychiatric settings.

Authors:  G J SARWER-FONER; E K KORANYI; J MACKAY; H GRAUER
Journal:  Can Med Assoc J       Date:  1959-11-01       Impact factor: 8.262

6.  Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice.

Authors:  Kinga Sałat; Anna Furgała-Wojas
Journal:  Molecules       Date:  2021-04-20       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.